Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.

Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

Anifrolumab effectively improved symptoms and reduced steroid use in Japanese patients with systemic lupus erythematosus.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

Anifrolumab improves quality of life and reduces steroid use in lupus patients.

Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.

Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.

Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Tofacitinib significantly improved skin and hair conditions without side effects.

Anifrolumab improves quality of life and reduces steroid use in SLE patients.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.

Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Tofacitinib is a promising treatment for children with rheumatic diseases.